ABSK111 / Abbisko - LARVOL DELTA

Discovery and characterization of ABSK111, a selective, CNS-penetrable, and broad-spectrum EGFR inhibitor targeting exon20 insertion, atypical and extracellular mutations (AACR 2022) - "Pharmacodynamic analysis of endpoint samples from efficacy study showed sustained inhibition of p-ERK, which was superior to the approved exon20 insertion inhibitor mobocertinib. Taken together, these results demonstrate the ability of ABSK111 to inhibit a broad spectrum of EGFR and HER2 mutations, including exon20 insertions, atypical and extracellular mutations, while sparing the WT form of EGFR. In addition to the application in NSCLC, the activity against EGFR extracellular mutations and the ability to penetrate into brain suggest the application of ABSK111 in glioblastoma multiforme (GBM)."

EGFR exon 20 • Late-breaking abstract • Brain Cancer • Glioblastoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2